Gene Therapy for Atherosclerotic Cardiovascular Disease: A Time for Optimism and Caution

2000 ◽  
Vol 75 (8) ◽  
pp. 831-834 ◽  
Author(s):  
Timothy O'Brien ◽  
Robert D. Simari
Keyword(s):  
Cardiovascular Disease ◽  
Gene Therapy ◽  
Atherosclerotic Cardiovascular Disease

Pigment Epithelium-Derived Factor: A Novel Therapeutic Target for Cardiometabolic Diseases and Related Complications

2018 ◽  
Vol 25 (13) ◽  
pp. 1480-1500 ◽  
Author(s):  
Sho-ichi Yamagishi ◽  
Takanori Matsui
Keyword(s):  
Cardiovascular Disease ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Visceral Obesity ◽  
Retinal Pigment Epithelial Cells ◽  
Atherosclerotic Cardiovascular Disease ◽  
Cardiometabolic Diseases ◽  
The Metabolic Syndrome ◽  
Pigment Epithelium Derived Factor ◽  
Cardiometabolic Disorders

Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors, serpins. It was first identified as a neuronal differentiating factor secreted by human retinal pigment epithelial cells, and then found to be the most potent inhibitor of pathological angiogenesis in mammalian eyes. Recently, PEDF has been shown not only to suppress oxidative stress and inflammatory reactions in vascular wall cells, T cells and macrophages, and adipocytes, but also to exert antithrombotic and anti-fibrotic properties, thereby protecting against the development and progression of various cardiometabolic diseases and related complications. Furthermore, accumulating evidence has suggested that circulating PEDF levels may be a biomarker of severity and prognosis of these devastating disorders. Number of subjects with visceral obesity and insulin resistance is increasing, and the metabolic syndrome and its related complications, such as diabetes, nonalcoholic fatty liver disease/non-alcoholic steatohepatits, and atherosclerotic cardiovascular disease are a growing health challenge. Therefore, in this study, we review the pathophysiological role of PEDF in obesity and metabolic disorders, cardiovascular disease, diabetic eye and kidney complications, liver diseases, and reproductive system disorders, and discuss the potential clinical utility of modulating the expression and actions of PEDF for preventing these cardiometabolic disorders. We also refer to the clinical value of PEDF as a biomarker in cardiometabolic complications.

Plant n-3 PUFA intake may lower the risk of atherosclerotic cardiovascular disease only among subjects with a low intake of marine n-3 PUFAs

2021 ◽  
Author(s):  
Christian S. Bork ◽  
Søren Lundbye-Christensen ◽  
Stine K. Venø ◽  
Anne N. Lasota ◽  
Erik B. Schmidt ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Atherosclerotic Cardiovascular Disease ◽  
Pufa Intake

Atherosclerotic Cardiovascular Disease in Individuals with Hepatitis C Viral Infection

2021 ◽  
Vol 23 (5) ◽  
Author(s):  
Alison L. Bailey ◽  
Saif Al-Adwan ◽  
Eliea Sneij ◽  
Nicholas Campbell ◽  
Matthew E. Wiisanen
Keyword(s):  
Cardiovascular Disease ◽  
Hepatitis C ◽  
Viral Infection ◽  
Atherosclerotic Cardiovascular Disease
Sign in / Sign up

Export Citation Format

Share Document